Phase 2 ARTEMIS-UC trial demonstrates tulisokibart improves remission rates in ulcerative colitis, suggesting effective treatment.
Introduction: Tulisokibart is a monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), a key regulator of inflammation and fibrosis in ulcerative colitis (UC). The Phase 2 ARTEMIS-UC study showed that a higher percentage of tulisokibart participants achieved clinical remission after 12 weeks compared to placebo [1].
No takes yet. Share an insight, caveat, or question.
Soßdorf et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: